Get the Stockscreener App
1.86
2.20%
0.04
Gain Therapeutics Inc stock is traded at $1.86, with a volume of 308.82K.
It is up +2.20% in the last 24 hours and down -4.62% over the past month.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.
See More
Previous Close:
$1.82
Open:
$1.81
24h Volume:
308.82K
Relative Volume:
0.46
Market Cap:
$79.34M
Revenue:
$55,200
Net Income/Loss:
$-21.24M
P/E Ratio:
-3.1606
EPS:
-0.5885
Net Cash Flow:
$-19.37M
1W Performance:
+12.73%
1M Performance:
-4.62%
6M Performance:
-40.76%
1Y Performance:
+5.08%
1-Day Range:
$1.75
$1.87
1-Week Range:
$1.62
$1.95
52-Week Range:
$1.41
$4.34
Gain Therapeutics Inc Stock (GANX) Company Profile
Name
Gain Therapeutics Inc
Sector
Industry
Phone
(301) 500-1556
Address
4800 HAMPDEN LANE, BETHESDA
Compare GANX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
1.86 | 77.63M | 55,200 | -21.24M | -19.37M | -0.5885 |
VRTX
Vertex Pharmaceuticals Inc
|
443.11 | 110.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
632.02 | 66.53B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
824.26 | 50.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.62 | 39.45B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
152.49 | 32.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Aug-14-24 | Resumed | Oppenheimer | Outperform |
| Apr-12-21 | Initiated | BTIG Research | Buy |
| Apr-12-21 | Initiated | Oppenheimer | Outperform |
Gain Therapeutics Inc Stock (GANX) Latest News
Gain Therapeutics stock maintained at Outperform by Oppenheimer - Investing.com
Gain Therapeutics expands ‘compelling’ evidence base for Parkinson’s candidate - Yahoo Finance
Gain Therapeutics Reports Interim Data for Parkinson’s Candidate - TipRanks
GT-02287 shows biomarker, symptom stability in Gain (GANX) Parkinson’s study - Stock Titan
Gain Therapeutics says MDS-UPDRS scores remain stable after 150 days of GT-2287 treatment - marketscreener.com
Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026 - The Manila Times
Gain Therapeutics presents phase 1b data on Parkinson’s drug By Investing.com - Investing.com Canada
Gain Therapeutics presents phase 1b data on Parkinson’s drug - Investing.com
Parkinson’s patients report better smell, sleep, balance on experimental GT-02287 - Stock Titan
Bial Announces Completion of Phase 2b ACTIVATE Study with BIA 28-6156 in GBA1-Associated Parkinson’s - Yahoo Finance
Gain Therapeutics (GANX) Bounces Back: Testing Key Resistance at $1.87Overvalued Signals - Newser
Gain Therapeutics Inc. (GANX) Q1 2026 Earnings: Narrower Loss Surpasses Estimates, Stock Edges HigherSaaS Earnings Trends - Newser
Gain Therapeutics (GANX) Edges Higher as Biotech Sector Shows Mixed SignalsTrading Community Hub - Newser
3 Parkinson's Biotech Stocks Analysts Think Are Wildly Mispriced - Moomoo
Gain Therapeutics (GANX) shares edge higher after narrower-than-expected Q1 loss - MSN
GANX Technical Analysis | Trend, Signals & Chart Patterns | GAIN THERAPEUTICS INC (NASDAQ:GANX) - ChartMill
GANX Gain Therapeutics EPS beats by 26 but shares decline 27 amid revenue concernsMarket Buzz Alerts - Newser
Roth MKM Maintains Gain Therapeutics(GANX.US) With Buy Rating, Cuts Target Price to $8 - Moomoo
Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update - Black Hills Pioneer
Gain Therapeutics: Remain on Track to Begin Our Phase 2 Study in 3Q 2026 >GANX - Moomoo
Gain Therapeutics (NASDAQ: GANX) posts higher Q1 2026 loss and flags going concern risk - Stock Titan
Gain Therapeutics reports Q1 2026 net loss $5.61M; cash $16.5M; R&D and G&A rise - TradingView
Gain Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Gain Therapeutics (NASDAQ: GANX) details Q1 2026 loss and Parkinson’s trial plans - Stock Titan
Gain Therapeutics (NASDAQ:GANX) Releases Quarterly Earnings Results, Hits Expectations - MarketBeat
Gain Therapeutics beats Q1 loss estimates, shares rise 3% By Investing.com - Investing.com Canada
Gain Therapeutics (GANX) Shares Edge Higher After Narrower-Than-Expected Q1 Loss - Yahoo Finance
Gain Therapeutics: Expect to Receive FDA Clearance of Our GT-02287 IND During 2Q 2026 >GANX - Moomoo
Gain Therapeutics Q1 loss per share narrows - TradingView
Gain Therapeutics beats Q1 loss estimates, shares rise 3% - Investing.com
Gain Parkinson’s trial sees 81% biomarker drop, Phase 2 planned - Stock Titan
GANX (Gain Therapeutics) EPS beats by 26%, but shares decline 2.7% amid revenue concerns.Stock Analysis Community - Newser
Gain Therapeutics Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView
Gain Therapeutics, Inc. (NASDAQ:GANX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
3 US Biotechs Developing Parkinson’s Therapies - Sahm
[ARS] Gain Therapeutics, Inc. SEC Filing - Stock Titan
[DEF 14A] Gain Therapeutics, Inc. Definitive Proxy Statement - Stock Titan
Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026 - marketscreener.com
Gain Flat Ahead of Arizona Conference - Baystreet.ca
Gain Therapeutics, Inc. to Present Update on Parkinson’s Disease Drug GT-02287 at 3rd International GBA1 Meeting 2026 - Quiver Quantitative
Gain to present Parkinson’s drug update at Phoenix GBA1 meeting - Stock Titan
GANX Gain Therapeutics posts narrower Q4 2025 loss than estimates, but shares fall 2.39%.Unusual Options - Newser
GANX | Gain Therapeutics, Inc. Common Insider Trading - Quiver Quantitative
Breakout Watch: Does Gain Therapeutics Inc have a sustainable dividendMarket Risk Analysis & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
GANX Should I Buy - Intellectia AI
Technical Analysis: Will Gain Therapeutics Inc benefit from green energy policiesQuarterly Trade Review & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Weekly Recap: Is Gain Therapeutics Inc a strong candidate for buy and holdMarket Sentiment Report & Real-Time Market Trend Scan - baoquankhu1.vn
Death Cross: Is Gain Therapeutics Inc attractive for institutional investorsPortfolio Value Report & Real-Time Stock Entry Alerts - baoquankhu1.vn
Stop Loss: What hedge funds are buying Gain Therapeutics IncInsider Selling & Long-Term Growth Stock Strategies - baoquankhu1.vn
Gain Therapeutics Inc Stock (GANX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.67%
1.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):